Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | GRM5 | P41594 | 12/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30861099 | 0.87 | MAPK1 (0.52) | MAPK1DRD2DRD3GRM5NPC1 | |
| SCHEMBL4052245 | 0.85 | MAPK1 (0.67) | MAPK1DRD2DRD3GRM5NPC1 | |
| SCHEMBL30513269 | 0.83 | MAPK1 (0.63) | MAPK1DRD2DRD3GRM5NPC1 | |
| SCHEMBL741667 | 0.79 | MAPK1 (0.59) | MAPK1DRD2DRD3GRM5 | |
| SCHEMBL30916184 | 0.78 | MAPK1 (0.58) | MAPK1GRM5 | |
| SCHEMBL741598 | 0.78 | MAPK1 (0.58) | MAPK1GRM5 | |
| SCHEMBL13413141 | 0.76 | MAPK1 (0.59) | MAPK1DRD2DRD3GRM5NPC1 | |
| SCHEMBL30513280 | 0.76 | MAPK1 (0.55) | MAPK1DRD2DRD3GRM5 | |
| Propionic Acid SCHEMBL29011051 | 0.74 | MAPK1 (0.50) | MAPK1DRD2DRD3GRM5NPC1 | |
| SCHEMBL14970397 | 0.72 | MAPK1 (0.51) | MAPK1DRD2DRD3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936475-B | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2024-05-10 | — | — | CN | disclosed |
| WO-2024088407-A1 | NITROGEN-CONTAINING FUSED RING COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州圣域生物医药科技有限公司 | 2024-05-02 | — | — | WO | disclosed |
| CN-110582493-B | Benzoxazole derivatives as immunomodulators | 因赛特公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11566026-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| CN-111936475-A | Immunomodulator, composition and preparation method thereof | 贝达药业股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566026-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | MAPK1 3802/4885DRD2 2789/4885DRD3 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.